This company has been acquired
Prometheus Biosciences Management
Management criteria checks 1/4
Prometheus Biosciences' CEO is Mark McKenna, appointed in Sep 2019, he has a tenure of 3.75 years. His total yearly compensation is $19.94M , comprised of 3% salary and 97% bonuses, including company stock and options. He directly owns 0.29% of the company’s shares, worth $28.17M. The average tenure of the management team and the board of directors is 2.5 years and 2.3 years respectively.
Key information
Mark McKenna
Chief executive officer
US$19.9m
Total compensation
| CEO salary percentage | 3.0% |
| CEO tenure | 3.8yrs |
| CEO ownership | 0.3% |
| Management average tenure | 2.5yrs |
| Board average tenure | 2.3yrs |
Recent management updates
Recent updates
We Think Prometheus Biosciences (NASDAQ:RXDX) Can Afford To Drive Business Growth
May 17
Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation
Dec 03We Think Prometheus Biosciences (NASDAQ:RXDX) Needs To Drive Business Growth Carefully
Aug 19Prometheus Biosciences GAAP EPS of -$0.86 beats by $0.06, revenue of $1.26M beats by $0.8M
Aug 11We're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash Wisely
May 04Prometheus: Biotech To Watch With A Monoclonal Antibody For Immune-Mediated Diseases
Dec 08Prometheus Biosciences (NASDAQ:RXDX) Is In A Good Position To Deliver On Growth Plans
Nov 16Prometheus Biosciences: Precision Medicine For IBD
Sep 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$151m |
| Dec 31 2022 | US$20m | US$592k | -US$142m |
| Sep 30 2022 | n/a | n/a | -US$133m |
| Jun 30 2022 | n/a | n/a | -US$123m |
| Mar 31 2022 | n/a | n/a | -US$108m |
| Dec 31 2021 | US$12m | US$566k | -US$90m |
| Sep 30 2021 | n/a | n/a | -US$69m |
| Jun 30 2021 | n/a | n/a | -US$50m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$3m | US$500k | -US$31m |
| Dec 31 2019 | US$976k | US$157k | -US$17m |
Compensation vs Market: Mark's total compensation ($USD19.94M) is above average for companies of similar size in the US market ($USD8.17M).
Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.
CEO
Mark McKenna (43 yo)
3.8yrs
Tenure
US$19,936,088
Compensation
Mr. Mark C. Mckenna serves as President, Chief Executive Officer, Chairman of the Board at Prometheus Biosciences, Inc. since August 2021. He serves as Director of Rebalance Health, Inc. He serves as Execu...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.8yrs | US$19.94m | 0.29% $ 28.2m | |
| Chief Financial Officer | 2.8yrs | US$7.12m | 0.18% $ 17.6m | |
| Chief Operating Officer | 2.3yrs | US$6.16m | 0.035% $ 3.4m | |
| Chief Scientific Officer & Head of R&D | 1.5yrs | no data | no data | |
| Vice President of Investor Relations & Communications | no data | no data | no data | |
| General Counsel & Secretary | 2.6yrs | no data | no data | |
| Chief People Officer | 2.2yrs | no data | no data | |
| Chief Medical Officer | 4.8yrs | US$4.24m | 0% $ 0 | |
| Chief Development Officer of Diagnostics & Medical Laboratory Director | 3.5yrs | no data | no data | |
| Chief Business Officer | 2.4yrs | no data | no data | |
| Chief of Staff & VP of Business Operations | 2.4yrs | no data | no data | |
| Senior Vice President of Finance | no data | no data | no data |
2.5yrs
Average Tenure
53yo
Average Age
Experienced Management: RXDX's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.8yrs | US$19.94m | 0.29% $ 28.2m | |
| Independent Director | 2.1yrs | US$441.91k | 0% $ 0 | |
| Lead Independent Director | 2.8yrs | US$463.28k | 0.031% $ 3.0m | |
| Independent Director | 2.3yrs | US$442.29k | 0% $ 0 | |
| Independent Director | 2.3yrs | US$429.79k | 0% $ 0 | |
| Independent Director | 2.3yrs | US$444.04k | 0.0010% $ 100.4k | |
| Chairman of Scientific Advisory Board | 1.1yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.7yrs | US$439.79k | 0% $ 0 | |
| Director | 3.2yrs | US$424.79k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
2.3yrs
Average Tenure
62.5yo
Average Age
Experienced Board: RXDX's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.